Home › SEC Filings
SEC Filing Analysis
All Current Report (8-K)Annual Report (10-K)Quarterly Report (10-Q)Form 4 Insider TradesSC 13D Beneficial Ownership13F Institutional HoldingsPress ReleasesInsider Cluster ActivityInsider Buy Activity
Theme?
All themes Artificial IntelligenceSemiconductorsQuantum ComputingSpace & SatellitesRobotics & AutomationElectric VehiclesClean & Renewable EnergyBattery & Energy StorageNuclear & FusionCybersecurityCloud & SaaSFintech & PaymentsCrypto & BlockchainGenomics & Gene EditingBiotech & Drug DiscoveryE-commerce & PlatformsStreaming & Digital MediaGaming & EsportsDefense TechCannabis
| Ticker | Type | Sentiment | Impact | Summary | Date |
|---|---|---|---|---|---|
| IMUX | 8-K | neutral | 2/10 | Immunic filed an 8-K disclosing an updated corporate investor presentation on its website. The filing is a routine Regul | Jul 14, 2026 |
| SILO | PRESS-RELEASE | bullish | 4/10 | Silo Pharma announced via press release that its wholly owned AI-agent subsidiary, QwikAgents, has been accepted into th | Jul 14, 2026 |
| IKT | 8-K | bearish | 6/10 | Inhibikase Therapeutics sold 25,000,000 shares to RA Capital Management via its ATM facility for $50 million in gross pr | Jul 14, 2026 |
| VYNE | 425, 8-K | neutral | 5/10 | VYNE Therapeutics filed an 8-K (Item 7.01) furnishing an investor presentation by Yarrow Bioscience, the merger partner | Jul 14, 2026 |
| SNDX | 8-K | bullish | 7/10 | Syndax held an R&D event unveiling two new pipeline assets: SNDX-4321, a mutant-selective allosteric EGFR inhibitor for | Jul 14, 2026 |
| ERNA | PRESS-RELEASE | neutral | 3/10 | Ernexa Therapeutics released a CEO Corner video discussing ERNA-101, its lead cell therapy candidate for ovarian cancer, | Jul 14, 2026 |
| NXTC | 425, 8-K | bullish | 7/10 | NextCure (NXTC) announces a reverse merger with private biotech Avere Therapeutics, structured as a two-step merger wher | Jul 14, 2026 |
| NXTC | 8-K | bearish | 7/10 | NextCure (NXTC) entered into a definitive agreement to merge with Avere Therapeutics in a reverse merger, where Avere sh | Jul 14, 2026 |
| KURA | PRESS-RELEASE | neutral | 5/10 | Kura Oncology announced an oral presentation of updated Phase 1a data from its FIT-001 trial of darlifarnib plus cabozan | Jul 14, 2026 |
| SPRO | 8-K | bullish | 8/10 | Spero Therapeutics in-licensed SP001 (IBI355), a Phase 2-ready anti-CD40L antibody, from Innovent Biologics for $35M upf | Jul 14, 2026 |
| AVIR | PRESS-RELEASE | bullish | 5/10 | Atea Pharmaceuticals initiated a first-in-human Phase 1 trial of AT-587 for hepatitis E virus (HEV), a disease with no a | Jul 14, 2026 |
| ANRO | 8-K | bearish | 6/10 | Alto Neuroscience entered into an underwriting agreement for a $100M public offering of 3,776,436 shares at $26.48 per s | Jul 14, 2026 |
| AEON | EFFECT | bearish | 8/10 | AEON Biopharma's S-1 IPO registration became effective on July 13, 2026, allowing the company to proceed with a highly d | Jul 14, 2026 |
| QTTB | EFFECT | neutral | 3/10 | Q32 Bio's S-3 shelf registration (File No. 333-297027) became effective on July 13, 2026, allowing the company to sell e | Jul 14, 2026 |
| RDHL | EFFECT | bearish | 6/10 | The SEC declared effective RedHill Biopharma's F-3 shelf registration (File No. 333-297223) on July 13, 2026. This enabl | Jul 14, 2026 |
| AKTX | EFFECT | bearish | 6/10 | Akari Therapeutics' S-3 registration statement (file 333-297257) became effective on July 13, 2026, allowing selling sha | Jul 14, 2026 |
| EDSA | EFFECT | bearish | 4/10 | Edesa Biotech received SEC effectiveness on its S-3 shelf registration (file 333-297251) on July 13, 2026, 12 days after | Jul 14, 2026 |
| IMMP | 6-K | mixed | 6/10 | Immutep reported mature overall survival data from the Phase I INSIGHT-003 trial in 1L non-squamous NSCLC, showing media | Jul 14, 2026 |
| ANRO | 424B5 | bearish | 6/10 | Alto Neuroscience is conducting a $100M underwritten public offering of 3,776,436 shares at $26.48 per share (at-the-mar | Jul 14, 2026 |
| SAFX | S-4/A | neutral | 5/10 | XCF Global filed Amendment No. 1 to its S-4 registration statement on July 13, 2026, seeking stockholder approval for a | Jul 14, 2026 |
| SPRO | PRESS-RELEASE | bullish | 7/10 | Spero Therapeutics in-licensed global rights (ex-China) to SP001 (IBI355), a third-generation anti-CD40L antibody, from | Jul 14, 2026 |
| PMN | PRESS-RELEASE | bullish | 6/10 | ProMIS Neurosciences announced at AAIC 2026 that its lead Alzheimer's candidate, PMN310, demonstrated a dose-dependent r | Jul 14, 2026 |
| BBIO | CLUSTER | neutral | 3/10 | Two BridgeBio directors executed open-market sales totaling $11.56M on July 9, 2026, following derivative exercises. Dir | Jul 14, 2026 |
| NBIX | CLUSTER | neutral | 3/10 | Two senior NBIX executives, Chief Legal Officer Darin Lippoldt and Chief Regulatory Officer Ingrid Delaet, exercised and | Jul 14, 2026 |
| UTHR | CLUSTER | neutral | 2/10 | CEO Martine Rothblatt and Director Jan Malcolm sold a combined $503K in open-market UTHR shares on July 10, 2026. The CE | Jul 14, 2026 |
| PTCT | CLUSTER | neutral | 2/10 | Two PTCT insiders, the Chief Technical Operations Officer and the EVP & CLO, sold a combined ~$267K in open-market sales | Jul 14, 2026 |
| ERAS | PRESS-RELEASE | bearish | 7/10 | Erasca has priced an upsized public offering of 31,428,572 shares at $17.50/share, expecting ~$550M in gross proceeds. T | Jul 13, 2026 |
| MESO | PRESS-RELEASE | neutral | 5/10 | Mesoblast announced completion of enrollment (at least 300 patients) in its pivotal Phase 3 trial of rexlemestrocel-L fo | Jul 13, 2026 |
| CMND | 6-K | neutral | 3/10 | Clearmind Medicine filed a 6-K with a press release reporting positive early investigator feedback from its ongoing Phas | Jul 13, 2026 |
| GRTX | 8-K | neutral | 4/10 | Galera Therapeutics effected a 1-for-200 reverse stock split, effective July 12, 2026, and began trading split-adjusted | Jul 13, 2026 |